The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Galectin-3 May Be a Biomarker for Cardiovascular Disease in RA

Galectin-3 May Be a Biomarker for Cardiovascular Disease in RA

March 25, 2019 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Recent findings suggest an association between increased galectin-3 levels and markers of myocardial function, atherosclerosis and vascular fibrosis in patients with rheumatoid arthritis (RA). Thus, galectin-3 may be a biomarker for early prediction of cardiovascular disease in RA patients.1 This could potentially increase the life expectancy of RA patients, suggests study investigator Panagiota Anyfanti, MD, PhD, a research fellow in the Third Department of Internal Medicine at Papageorgiou Hospital, Thessaloniki, Greece.

You Might Also Like
  • Cardiovascular Disease Risk High in RA Patients
  • Insight into Endothelial Dysfunction in Early SLE Patients without Cardiovascular Disease
  • Depression May Increase Risk of Cardiovascular Disease for RA Patients
Also By This Author
  • The ACR Lobbies Against New Part B Drug Cost Adjustment Rule

Galectin-3 & Cardiovascular Disease
To understand whether galectin‐3 levels correlate with markers of vascular fibrosis, subclinical atherosclerosis and cardiac function in RA patients, Dr. Anyfanti and co-investigators evaluated both RA and non‐RA individuals who underwent applanation tonometry, carotid ultrasound and impedance cardiography, measuring arterial stiffness, subclinical atherosclerosis and myocardial function. Cardiovascular risk was estimated using the Framingham Heart Study. Serum levels of galectin‐3 were determined by enzyme‐linked immunosorbent assay.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study results showed galectin‐3 was elevated in RA patients compared with controls. This difference was no longer significant once adjusted for the presence of cardiovascular comorbidities. However, in a univariate analysis of the data, increased galectin‐3 levels significantly correlated with markers of vascular stiffness, atherosclerosis, myocardial bloodflow and contractibility, systemic vascular resistance and estimated cardiovascular risk.

In a multivariate analysis, an independent association was identified for galectin‐3 with both cardiac output and systemic vascular resistance.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We take the results of our study as evidence galectin-3 may be used as a biomarker of myocardial function and vascular fibrosis in patients with RA, as is the case with other high-cardiovascular risk populations, especially those with heart failure,” Dr. Anyfanti says.

Identifying Early Signs of Cardiovascular Risks
Increased cardiovascular risk in RA is considered inherent to the disease-mediated inflammatory processes. Although medical advances help patients experience fewer RA-related complications and less physical disability, cardiovascular mortality rates in RA have not substantially improved, Dr. Anyfanti says. Reasons for this lack of improvement include atherosclerosis and vascular fibrosis, which are clinically silent until the development of overt cardiovascular disease.

“The progress of these [diseases] can be slowed through early detection and improved monitoring in the subclinical stage. Subsequently, their clinical manifestations as cardiovascular disease could be deferred,” she says. “In this scope, it is important to identify robust biomarkers of atherosclerosis and cardiovascular fibrosis that can be successfully applied to patients suffering from RA who are at excess cardiovascular risk.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Anyfanti says the full extent of galectin-3 as a potential cardiac biomarker must be further examined in prospective studies. However, she confirms the presence of cardiovascular comorbidities has had a major effect on these study results and appears to substantially contribute to the association of galectin-3 with markers of cardiovascular health.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: cardiovascular, Cardiovascular disease, galectin‐3, Rheumatoid Arthritis (RA), risk

You Might Also Like:
  • Cardiovascular Disease Risk High in RA Patients
  • Insight into Endothelial Dysfunction in Early SLE Patients without Cardiovascular Disease
  • Depression May Increase Risk of Cardiovascular Disease for RA Patients
  • Cardiovascular Disease Mortality Risk Remains Higher for Patients with RA

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.